Philip Kantoff

Philip Kantoff led the pivotal IMPACT trial of sipuleucel-T (Provenge), the first FDA-approved cancer vaccine, demonstrating a survival benefit in metastatic castration-resistant prostate cancer and validating the concept that autologous dendritic cell-based immunotherapy can extend life in cancer patients. His trial established the paradigm of autologous cellular immunotherapy and provided critical clinical evidence for DC vaccine efficacy. He has contributed to development of next-generation DC vaccine approaches in prostate and other cancers. His clinical research was a landmark in cancer immunotherapy.